moomoo ID:0
Log Out
  • English
  • 中文繁体
  • 中文简体

Why Ventyx Biosciences Is Trading Higher By 70%, Here Are 46 Stocks Moving In Monday's Mid-Day Session

Benzinga Real-time News ·  09/13 00:46


  • Ventyx Biosciences, Inc. (NASDAQ:VTYX) shares jumped 70.4% to $39.37 after Oppenheimer maintained an Outperform rating on the stock and raised its price target from $40 to $65.
  • NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) gained 69% to $0.4664 after the company announced a 1-for-30 reverse stock split.
  • Arqit Quantum Inc. (NASDAQ:ARQQ) shares climbed 34.7% to $7.53. The company will present at the H.C. Wainwright 24th Annual Global Investment Conference later today.
  • InMed Pharmaceuticals Inc. (NASDAQ:INM) gained 32.5% to $14.60 after the company on Friday announced a $6 million private placement priced at $8.68 per share.
  • Ra Medical Systems, Inc. (NYSE:RMED) surged 28% to $0.1865 after the company announced a merger agreement with Catheter Precision. Catheter Precision will become a wholly owned subsidiary of Ra Medical.
  • Vinco Ventures, Inc. (NASDAQ:BBIG) gained 25% to $1.2500.
  • IHS Holding Limited (NYSE:IHS) jumped 19.2% to $7.47. IHS Holding, last month, said Q2 EPS results down year-over-year.
  • Gogoro Inc. (NASDAQ:GGR) gained 19.1% to $5.16. Gogoro recently launched its battery-swapping system and Smart scooters in the Tel Aviv metropolitan area.
  • Ribbon Communications Inc. (NASDAQ:RBBN) rose 19% to $3.8450.
  • Allego N.V. (NYSE:ALLG) gained 18.3% to $5.23.
  • Regulus Therapeutics Inc. (NASDAQ:RGLS) gained 16.8% to $1.94 after the company announced topline safety and PK data from its Phase 1 SAD clinical trial of RGLS8429. The study demonstrated that RGLS8429 has a favorable safety and PK profile.
  • IDEAYA Biosciences, Inc. (NASDAQ:IDYA) surged 15.6% to $10.70. IDEAYA Biosciences disclosed interim Phase 2 clinical results for darovasertib and crizotinib synthetic lethal combination in metastatic uveal melanoma.
  • Carvana Co. (NYSE:CVNA) rose 13.7% to $41.64. Piper Sandler upgraded Carvana from Neutral to Overweight and lowered the price target from $98 to $73.
  • POINT Biopharma Global Inc. (NASDAQ:PNT) gained 13.4% to $9.72 after the company published a poster at ESMO Congress 2022 highlighting updated safety and efficacy data from its Phase 3 SPLASH trial of PNT2002 in metastatic castration-resistant prostate cancer.
  • Sigma Lithium Corporation (NASDAQ:SGML) jumped 12.8% to $28.16.
  • Clovis Oncology, Inc. (NASDAQ:CLVS) rose 12.2% to $1.29 after the company said Rubraca (Rucaparib) as first-line maintenance treatment improves progression-free survival in women with advanced ovarian cancer across disease risk subgroups.
  • Auddia Inc. (NASDAQ:AUUD) surged 12% to $1.40.
  • Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) gained 10.8% to $42.98 after jumping 26% on Friday.
  • Genenta Science S.p.A. (NASDAQ:GNTA) gained 10.6% to $5.30.
  • NIO Inc. (NYSE:NIO) surged 10.2% to $21.13 following positive analyst coverage from Deutsche Bank and BofA.
  • NetScout Systems, Inc. (NASDAQ:NTCT) gained 9.7% to $33.70. The company, last month, posted upbeat quarterly earnings.
  • Reborn Coffee, Inc. (NASDAQ:REBN) rose 9.4% to $2.5924. Dennis R Egidi recently reported a 9.5% stake in Reborn Coffee.
  • Eve Holding, Inc. (NYSE:EVEX) gained 9.2% to $8.42. United recently announced a $15 million investment in Eve Air Mobility and a conditional purchase agreement for 200 four-seat electric aircraft plus 200 options.
  • Asana, Inc. (NYSE:ASAN) gained 9% to $26.87. Asana's President, CEO and Director Dustin Moskovitz bought a total of 19,273,127 shares at an average price of $18.16.
  • Quhuo Limited (NASDAQ:QH) shares rose 7.5% to $2.96 after the company on Friday said it has determined not to proceed with its proposed offering and sale of securities.
  • Hyperfine, Inc. (NASDAQ:HYPR) rose 7.3% to $1.3090 after declining 6% on Friday. Hyperfine, last month, reported worse-than-expected Q2 EPS and sales results and issued FY22 sales guidance below estimates.
  • Bristol-Myers Squibb Company (NYSE:BMY) rose 5.6% to $74.11. The FDA approved Bristol Myers Squibb Co's Sotyktu (deucravacitinib), an allosteric tyrosine kinase 2 (TYK2) inhibitor, for moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Atlantic Equities maintained Bristol-Myers Squibb with an Overweight and raised the price target from $83 to $87.
  • Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) rose 4.3% to $1.35. The U.S. Food and Drug Administration has approved the company's lead asset ROLVEDON (eflapegrastim-xnst) injection to decrease the incidence of infection, as manifested by febrile neutropenia.


  • Akari Therapeutics, Plc (NASDAQ:AKTX) shares dropped 25% to $0.7803 after the company announced a $12.75 million registered direct offering.
  • Tuesday Morning Corporation (NASDAQ:TUEM) fell 22.7% to $0.2175 after the company secured commitment for strategic investment from group led by Retail Ecommerce Ventures, the owner of Pier 1 Imports and top consumer brands.
  • Yoshiharu Global Co. (NASDAQ:YOSH) shares fell 22.5% to $3.2301. The company, on Friday, priced its IPO at $4 per share.
  • DICE Therapeutics, Inc. (NASDAQ:DICE) fell 19.6% to $18.20. Stifel, last week, initiated coverage on the stock with a Buy rating and a $37 price target.
  • CleanTech Acquisition Corp. (NASDAQ:CLAQ) dropped 17.7% to $5.02. CleanTech Acquisition and Nauticus Robotics completed business combination to trade under "KITT" effective September 13.
  • Apexigen, Inc. (NASDAQ:APGN) declined 16.6% to $6.35 as the company announced the presentation of new data from a Phase 2 trial evaluating sotigalimab (sotiga) in combination with neoadjuvant chemoradiation for resectable esophageal and gastroesophageal junction (GEJ) cancers.
  • Leap Therapeutics, Inc. (NASDAQ:LPTX) dropped 15.3% to $1.43.
  • Codere Online Luxembourg, S.A. (NASDAQ:CDRO) fell 15.6% to $2.70. Codere Online recently reported Q2 sales results.
  • MOGU Inc. (NYSE:MOGU) fell 13.6% to $2.2475. Mogu's board of directors, on Friday, authorized a new share repurchase program of up to $10 million of its shares.
  • Nuwellis, Inc. (NASDAQ:NUWE) fell 12.1% to $0.7469.
  • Entrada Therapeutics, Inc. (NASDAQ:TRDA) dropped 11.4% to $13.21. Entrada Therapeutics, last month, posted a Q2 loss of $0.74 per share.
  • ShiftPixy, Inc. (NASDAQ:PIXY) fell 9.8% to $31.06 after gaining 11% on Friday.
  • Azure Power Global Limited (NYSE:AZRE) dropped 9.3% to $5.32.
  • Great Panther Mining Limited (NYSE:GPL) declined 9.2% to $0.2144.
  • Immatics N.V. (NASDAQ:IMTX) fell 9% to $11.69.
  • Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) dropped 8.7% to $1.7250. Ayala Pharmaceuticals presented interim data from RINGSIDE pivotal Phase 2/3 trial of AL102 show confirmed partial response in desmoid tumors, at ESMO Congress.
  • Burning Rock Biotech Limited (NASDAQ:BNR) declined 7.2% to $3.33.
  • Digital Media Solutions, Inc. (NYSE:DMS) fell 6% to $2.0696. Digital Media Solutions shares climbed 72% on Friday after the company received a non-binding go-private proposal from Prism Data for $2.50 per share in cash.

This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors’ financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. Moomoo makes no representation or warranty as to its adequacy, completeness, accuracy or timeliness for any particular purpose of the above content.

Moomoo is a financial information and trading app offered by Moomoo Technologies Inc.
In the U.S., investment products and services available through the moomoo app are offered by Moomoo Financial Inc., a broker-dealer registered with the U.S. Securities and Exchange Commission (SEC) and a member of Financial Industry Regulatory Authority (FINRA)/Securities Investor Protection Corporation (SIPC).
In Singapore, investment products and services available through the moomoo app are offered through Moomoo Financial Singapore Pte. Ltd. regulated by the Monetary Authority of Singapore (MAS). Moomoo Financial Singapore Pte. Ltd. is a Capital Markets Services Licence (License No. CMS101000) holder with the Exempt Financial Adviser Status. This advertisement has not been reviewed by the Monetary Authority of Singapore.
In Australia, financial products and services available through the moomoo app are provided by Futu Securities (Australia) Ltd, an Australian Financial Services Licensee (AFSL No. 224663) regulated by the Australian Securities and Investment Commission (ASIC). Please read and understand our Financial Services Guide, Terms and Conditions, Privacy Policy and other disclosure documents which are available on our websites and Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd. and Futu Securities (Australia) Ltd are affiliated companies.